113 related articles for article (PubMed ID: 38061307)
21. Breast cancer risks in women with a family history of breast or ovarian cancer who have tested negative for a BRCA1 or BRCA2 mutation.
Metcalfe KA; Finch A; Poll A; Horsman D; Kim-Sing C; Scott J; Royer R; Sun P; Narod SA
Br J Cancer; 2009 Jan; 100(2):421-5. PubMed ID: 19088722
[TBL] [Abstract][Full Text] [Related]
22. Prevalence of germline pathogenic
Morgan RD; Burghel GJ; Flaum N; Bulman M; Clamp AR; Hasan J; Mitchell CL; Schlecht H; Woodward ER; Lallo FI; Crosbie EJ; Edmondson RJ; Wallace AJ; Jayson GC; Evans DGR
J Med Genet; 2019 May; 56(5):301-307. PubMed ID: 30683677
[TBL] [Abstract][Full Text] [Related]
23. Breast cancer risk in BRCA1/2 mutation carriers and noncarriers under prospective intensified surveillance.
Engel C; Fischer C; Zachariae S; Bucksch K; Rhiem K; Giesecke J; Herold N; Wappenschmidt B; Hübbel V; Maringa M; Reichstein-Gnielinski S; Hahnen E; Bartram CR; Dikow N; Schott S; Speiser D; Horn D; Fallenberg EM; Kiechle M; Quante AS; Vesper AS; Fehm T; Mundhenke C; Arnold N; Leinert E; Just W; Siebers-Renelt U; Weigel S; Gehrig A; Wöckel A; Schlegelberger B; Pertschy S; Kast K; Wimberger P; Briest S; Loeffler M; Bick U; Schmutzler RK;
Int J Cancer; 2020 Feb; 146(4):999-1009. PubMed ID: 31081934
[TBL] [Abstract][Full Text] [Related]
24. Comprehensive epithelial tubo-ovarian cancer risk prediction model incorporating genetic and epidemiological risk factors.
Lee A; Yang X; Tyrer J; Gentry-Maharaj A; Ryan A; Mavaddat N; Cunningham AP; Carver T; Archer S; Leslie G; Kalsi J; Gaba F; Manchanda R; Gayther S; Ramus SJ; Walter FM; Tischkowitz M; Jacobs I; Menon U; Easton DF; Pharoah P; Antoniou AC
J Med Genet; 2022 Jul; 59(7):632-643. PubMed ID: 34844974
[TBL] [Abstract][Full Text] [Related]
25. Breast and Prostate Cancer Risks for Male BRCA1 and BRCA2 Pathogenic Variant Carriers Using Polygenic Risk Scores.
Barnes DR; Silvestri V; Leslie G; McGuffog L; Dennis J; Yang X; Adlard J; Agnarsson BA; Ahmed M; Aittomäki K; Andrulis IL; Arason A; Arnold N; Auber B; Azzollini J; Balmaña J; Barkardottir RB; Barrowdale D; Barwell J; Belotti M; Benitez J; Berthet P; Boonen SE; Borg Å; Bozsik A; Brady AF; Brennan P; Brewer C; Brunet J; Bucalo A; Buys SS; Caldés T; Caligo MA; Campbell I; Cassingham H; Christensen LL; Cini G; Claes KBM; ; ; Cook J; Coppa A; Cortesi L; Damante G; Darder E; Davidson R; de la Hoya M; De Leeneer K; de Putter R; Del Valle J; Diez O; Ding YC; Domchek SM; Donaldson A; Eason J; Eeles R; Engel C; Evans DG; Feliubadaló L; Fostira F; Frone M; Frost D; Gallagher D; Gehrig A; Giraud S; Glendon G; Godwin AK; Goldgar DE; Greene MH; Gregory H; Gross E; Hahnen E; Hamann U; Hansen TVO; Hanson H; Hentschel J; Horvath J; ; ; Izatt L; Izquierdo A; James PA; Janavicius R; Jensen UB; Johannsson OT; John EM; Kramer G; Kroeldrup L; Kruse TA; Lautrup C; Lazaro C; Lesueur F; Lopez-Fernández A; Mai PL; Manoukian S; Matrai Z; Matricardi L; Maxwell KN; Mebirouk N; Meindl A; Montagna M; Monteiro AN; Morrison PJ; Muranen TA; Murray A; Nathanson KL; Neuhausen SL; Nevanlinna H; Nguyen-Dumont T; Niederacher D; Olah E; Olopade OI; Palli D; Parsons MT; Pedersen IS; Peissel B; Perez-Segura P; Peterlongo P; Petersen AH; Pinto P; Porteous ME; Pottinger C; Pujana MA; Radice P; Ramser J; Rantala J; Robson M; Rogers MT; Rønlund K; Rump A; Sánchez de Abajo AM; Shah PD; Sharif S; Side LE; Singer CF; Stadler Z; Steele L; Stoppa-Lyonnet D; Sutter C; Tan YY; Teixeira MR; Teulé A; Thull DL; Tischkowitz M; Toland AE; Tommasi S; Toss A; Trainer AH; Tripathi V; Valentini V; van Asperen CJ; Venturelli M; Viel A; Vijai J; Walker L; Wang-Gohrke S; Wappenschmidt B; Whaite A; Zanna I; Offit K; Thomassen M; Couch FJ; Schmutzler RK; Simard J; Easton DF; Chenevix-Trench G; Antoniou AC; Ottini L;
J Natl Cancer Inst; 2022 Jan; 114(1):109-122. PubMed ID: 34320204
[TBL] [Abstract][Full Text] [Related]
26. Germline molecular data in hereditary breast cancer in Brazil: Lessons from a large single-center analysis.
Sandoval RL; Leite ACR; Barbalho DM; Assad DX; Barroso R; Polidorio N; Dos Anjos CH; de Miranda AD; Ferreira ACSM; Fernandes GDS; Achatz MI
PLoS One; 2021; 16(2):e0247363. PubMed ID: 33606809
[TBL] [Abstract][Full Text] [Related]
27. Prevalence of specific and recurrent/founder pathogenic variants in BRCA genes in breast and ovarian cancer in North Africa.
ElBiad O; Laraqui A; El Boukhrissi F; Mounjid C; Lamsisi M; Bajjou T; Elannaz H; Lahlou AI; Kouach J; Benchekroune K; Oukabli M; Chahdi H; Ennaji MM; Tanz R; Sbitti Y; Ichou M; Ennibi K; Badaoui B; Sekhsokh Y
BMC Cancer; 2022 Feb; 22(1):208. PubMed ID: 35216584
[TBL] [Abstract][Full Text] [Related]
28. Evaluation of pathogenetic mutations in breast cancer predisposition genes in population-based studies conducted among Chinese women.
Zeng C; Guo X; Wen W; Shi J; Long J; Cai Q; Shu XO; Xiang Y; Zheng W
Breast Cancer Res Treat; 2020 Jun; 181(2):465-473. PubMed ID: 32318955
[TBL] [Abstract][Full Text] [Related]
29. Clinical utility of hereditary cancer panel testing: Impact of PALB2, ATM, CHEK2, NBN, BRIP1, RAD51C, and RAD51D results on patient management and adherence to provider recommendations.
Vysotskaia V; Kaseniit KE; Bucheit L; Ready K; Price K; Johansen Taber K
Cancer; 2020 Feb; 126(3):549-558. PubMed ID: 31682005
[TBL] [Abstract][Full Text] [Related]
30. Multi-gene panel testing for hereditary cancer predisposition in unsolved high-risk breast and ovarian cancer patients.
Crawford B; Adams SB; Sittler T; van den Akker J; Chan S; Leitner O; Ryan L; Gil E; van 't Veer L
Breast Cancer Res Treat; 2017 Jun; 163(2):383-390. PubMed ID: 28281021
[TBL] [Abstract][Full Text] [Related]
31. Evaluation of Polygenic Risk Scores for Breast and Ovarian Cancer Risk Prediction in BRCA1 and BRCA2 Mutation Carriers.
Kuchenbaecker KB; McGuffog L; Barrowdale D; Lee A; Soucy P; Dennis J; Domchek SM; Robson M; Spurdle AB; Ramus SJ; Mavaddat N; Terry MB; Neuhausen SL; Schmutzler RK; Simard J; Pharoah PDP; Offit K; Couch FJ; Chenevix-Trench G; Easton DF; Antoniou AC
J Natl Cancer Inst; 2017 Jul; 109(7):. PubMed ID: 28376175
[TBL] [Abstract][Full Text] [Related]
32. Identifying sequence variants contributing to hereditary breast and ovarian cancer in BRCA1 and BRCA2 negative breast and ovarian cancer patients.
Jarhelle E; Riise Stensland HMF; Hansen GÅM; Skarsfjord S; Jonsrud C; Ingebrigtsen M; Strømsvik N; Van Ghelue M
Sci Rep; 2019 Dec; 9(1):19986. PubMed ID: 31882575
[TBL] [Abstract][Full Text] [Related]
33. Pathogenic and likely pathogenic variants in PALB2, CHEK2, and other known breast cancer susceptibility genes among 1054 BRCA-negative Hispanics with breast cancer.
Weitzel JN; Neuhausen SL; Adamson A; Tao S; Ricker C; Maoz A; Rosenblatt M; Nehoray B; Sand S; Steele L; Unzeitig G; Feldman N; Blanco AM; Hu D; Huntsman S; Castillo D; Haiman C; Slavin T; Ziv E
Cancer; 2019 Aug; 125(16):2829-2836. PubMed ID: 31206626
[TBL] [Abstract][Full Text] [Related]
34. Prevalence of pathogenic BRCA1/2 germline mutations among 802 women with unilateral triple-negative breast cancer without family cancer history.
Engel C; Rhiem K; Hahnen E; Loibl S; Weber KE; Seiler S; Zachariae S; Hauke J; Wappenschmidt B; Waha A; Blümcke B; Kiechle M; Meindl A; Niederacher D; Bartram CR; Speiser D; Schlegelberger B; Arnold N; Wieacker P; Leinert E; Gehrig A; Briest S; Kast K; Riess O; Emons G; Weber BHF; Engel J; Schmutzler RK;
BMC Cancer; 2018 Mar; 18(1):265. PubMed ID: 29514593
[TBL] [Abstract][Full Text] [Related]
35. The identification of pathogenic variants in BRCA1/2 negative, high risk, hereditary breast and/or ovarian cancer patients: High frequency of FANCM pathogenic variants.
Schubert S; van Luttikhuizen JL; Auber B; Schmidt G; Hofmann W; Penkert J; Davenport CF; Hille-Betz U; Wendeburg L; Bublitz J; Tauscher M; Hackmann K; Schröck E; Scholz C; Wallaschek H; Schlegelberger B; Illig T; Steinemann D
Int J Cancer; 2019 Jun; 144(11):2683-2694. PubMed ID: 30426508
[TBL] [Abstract][Full Text] [Related]
36. Utility of a mainstreamed genetic testing pathway in breast and ovarian cancer patients during the COVID-19 pandemic.
Benusiglio PR; Korenbaum C; Vibert R; Ezenfis J; Geoffron S; Paul C; Richard S; Byrde V; Lejeune M; Guillerm E; Basset N; Lotz JP; Chabbert-Buffet N; Gligorov J; Coulet F
Eur J Med Genet; 2020 Dec; 63(12):104098. PubMed ID: 33186762
[TBL] [Abstract][Full Text] [Related]
37. Detection of pathogenic variants in breast cancer susceptibility genes in bilateral breast cancer.
Evans DG; Burghel GJ; Schlecht H; Harkness EF; Gandhi A; Howell SJ; Howell A; Forde C; Lalloo F; Newman WG; Smith MJ; Woodward ER
J Med Genet; 2023 Oct; 60(10):974-979. PubMed ID: 37055167
[TBL] [Abstract][Full Text] [Related]
38. Evaluation of BRCA1/2 mutational status among German and Austrian women with triple-negative breast cancer.
Muendlein A; Rohde BH; Gasser K; Haid A; Rauch S; Kinz E; Drexel H; Hofmann W; Schindler V; Kapoor R; Decker T; Lang AH
J Cancer Res Clin Oncol; 2015 Nov; 141(11):2005-12. PubMed ID: 25971625
[TBL] [Abstract][Full Text] [Related]
39. Characterization of the Cancer Spectrum in Men With Germline BRCA1 and BRCA2 Pathogenic Variants: Results From the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA).
Silvestri V; Leslie G; Barnes DR; ; Agnarsson BA; Aittomäki K; Alducci E; Andrulis IL; Barkardottir RB; Barroso A; Barrowdale D; Benitez J; Bonanni B; Borg A; Buys SS; Caldés T; Caligo MA; Capalbo C; Campbell I; Chung WK; Claes KBM; Colonna SV; Cortesi L; Couch FJ; de la Hoya M; Diez O; Ding YC; Domchek S; Easton DF; Ejlertsen B; Engel C; Evans DG; Feliubadalò L; Foretova L; Fostira F; Géczi L; Gerdes AM; Glendon G; Godwin AK; Goldgar DE; Hahnen E; Hogervorst FBL; Hopper JL; Hulick PJ; Isaacs C; Izquierdo A; James PA; Janavicius R; Jensen UB; John EM; Joseph V; Konstantopoulou I; Kurian AW; Kwong A; Landucci E; Lesueur F; Loud JT; Machackova E; Mai PL; Majidzadeh-A K; Manoukian S; Montagna M; Moserle L; Mulligan AM; Nathanson KL; Nevanlinna H; Ngeow J; Nikitina-Zake L; Offit K; Olah E; Olopade OI; Osorio A; Papi L; Park SK; Pedersen IS; Perez-Segura P; Petersen AH; Pinto P; Porfirio B; Pujana MA; Radice P; Rantala J; Rashid MU; Rosenzweig B; Rossing M; Santamariña M; Schmutzler RK; Senter L; Simard J; Singer CF; Solano AR; Southey MC; Steele L; Steinsnyder Z; Stoppa-Lyonnet D; Tan YY; Teixeira MR; Teo SH; Terry MB; Thomassen M; Toland AE; Torres-Esquius S; Tung N; van Asperen CJ; Vega A; Viel A; Vierstraete J; Wappenschmidt B; Weitzel JN; Wieme G; Yoon SY; Zorn KK; McGuffog L; Parsons MT; Hamann U; Greene MH; Kirk JA; Neuhausen SL; Rebbeck TR; Tischkowitz M; Chenevix-Trench G; Antoniou AC; Friedman E; Ottini L
JAMA Oncol; 2020 Aug; 6(8):1218-1230. PubMed ID: 32614418
[TBL] [Abstract][Full Text] [Related]
40. A clinically structured and partnered approach to genetic testing in Trinidadian women with breast cancer and their families.
Donenberg T; George S; Ali J; Bravo G; Hernandez K; Sookar N; Ashing KT; Narod SA; Akbari MR; Hurley J
Breast Cancer Res Treat; 2019 Apr; 174(2):469-477. PubMed ID: 30515680
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
